JP2016519651A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519651A5 JP2016519651A5 JP2016501335A JP2016501335A JP2016519651A5 JP 2016519651 A5 JP2016519651 A5 JP 2016519651A5 JP 2016501335 A JP2016501335 A JP 2016501335A JP 2016501335 A JP2016501335 A JP 2016501335A JP 2016519651 A5 JP2016519651 A5 JP 2016519651A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- amino acid
- diphtheria toxin
- seq
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102220212165 rs75270082 Human genes 0.000 claims 76
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 22
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 22
- 125000000539 amino acid group Chemical group 0.000 claims 19
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 15
- 230000004048 modification Effects 0.000 claims 15
- 238000012986 modification Methods 0.000 claims 15
- 150000001413 amino acids Chemical group 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 102000000588 Interleukin-2 Human genes 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 102000000646 Interleukin-3 Human genes 0.000 claims 4
- 108010002386 Interleukin-3 Proteins 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 229940076264 interleukin-3 Drugs 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 3
- 230000009401 metastasis Effects 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102220511774 Adenylosuccinate lyase_S31N_mutation Human genes 0.000 claims 2
- 102220583903 Cellular tumor antigen p53_V97A_mutation Human genes 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 102220630956 Receptor-interacting serine/threonine-protein kinase 1_D30N_mutation Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 238000002407 reforming Methods 0.000 claims 2
- 102200058202 rs180177153 Human genes 0.000 claims 2
- 102220058321 rs730881995 Human genes 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- -1 148 or 200 Chemical compound 0.000 claims 1
- USWINTIHFQKJTR-UHFFFAOYSA-N 3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C=C(S(O)(=O)=O)C(O)=CC2=C1 USWINTIHFQKJTR-UHFFFAOYSA-N 0.000 claims 1
- ZUQOBHTUMCEQBG-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-1,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(O)=C2C(N)=CC=C(S(O)(=O)=O)C2=C1 ZUQOBHTUMCEQBG-UHFFFAOYSA-N 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 102220597747 Mitochondrial basic amino acids transporter_I290N_mutation Human genes 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029098 Neoplasm skin Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 102220510219 Poly(A)-specific ribonuclease PNLDC1_S31G_mutation Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000023965 endometrium neoplasm Diseases 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000025189 neoplasm of testis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 102200042996 rs1057521927 Human genes 0.000 claims 1
- 102220126666 rs886044334 Human genes 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 208000013076 thyroid tumor Diseases 0.000 claims 1
- 208000025421 tumor of uterus Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361799910P | 2013-03-15 | 2013-03-15 | |
| US61/799,910 | 2013-03-15 | ||
| PCT/US2014/023761 WO2014150600A2 (en) | 2013-03-15 | 2014-03-11 | Modified toxins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016519651A JP2016519651A (ja) | 2016-07-07 |
| JP2016519651A5 true JP2016519651A5 (https=) | 2017-04-13 |
Family
ID=51581612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501335A Pending JP2016519651A (ja) | 2013-03-15 | 2014-03-11 | 改質された毒素 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10059750B2 (https=) |
| EP (1) | EP2968450A4 (https=) |
| JP (1) | JP2016519651A (https=) |
| CA (1) | CA2902905A1 (https=) |
| HK (1) | HK1220376A1 (https=) |
| WO (1) | WO2014150600A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968450A4 (en) | 2013-03-15 | 2016-10-26 | Angelica Therapeutics Inc | MODIFIED TOXINS |
| WO2016204525A1 (ko) * | 2015-06-19 | 2016-12-22 | 엘지전자(주) | 터치 패널 및 표시 장치 |
| CN117659160A (zh) * | 2015-09-11 | 2024-03-08 | 小利兰·斯坦福大学托管委员会 | 生物相关正交细胞因子/受体对 |
| US10899829B2 (en) | 2016-02-23 | 2021-01-26 | Indiana University Research And Technology Corporation | Emapii neutralizing antibody limits influenza A virus (IAV)-induced lung injury |
| JP7422480B2 (ja) * | 2016-05-04 | 2024-01-26 | アムジエン・インコーポレーテツド | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
| ES2973548T3 (es) | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| US11219680B2 (en) | 2017-02-24 | 2022-01-11 | Merck Sharp & Dohme Corp. | Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US12144855B2 (en) | 2018-04-30 | 2024-11-19 | Merck Sharp & Dohme Llc | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres |
| EP3788143B1 (en) * | 2018-04-30 | 2023-06-28 | Merck Sharp & Dohme LLC | Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide |
| EP3787673A4 (en) | 2018-04-30 | 2022-04-27 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates |
| CN111944036B (zh) * | 2019-05-14 | 2024-09-06 | 上海盖浦生物科技有限公司 | 一种增殖免疫细胞的突变体蛋白 |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| WO2021222150A2 (en) * | 2020-04-28 | 2021-11-04 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4830962A (en) | 1984-02-09 | 1989-05-16 | Cetus Corporation | Recombinant diphtheria toxin fragments |
| US4894443A (en) | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
| US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US5792458A (en) | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
| US5785973A (en) | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines |
| WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| EP0945515A3 (en) | 1989-11-06 | 2002-08-21 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
| EP0438310A1 (en) | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
| WO1991013090A1 (en) | 1990-03-02 | 1991-09-05 | Diane Williams | Improved chimeric toxins |
| WO1992006117A1 (en) | 1990-09-28 | 1992-04-16 | Seragen, Inc. | Inhibiting unwanted immune responses |
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| US5695983A (en) | 1990-12-18 | 1997-12-09 | The General Hospital Corporation | Salmonella vaccines |
| IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| CA2135052A1 (en) | 1992-05-06 | 1993-11-11 | R. John Collier | Diphtheria toxin receptor-binding region |
| PT652758E (pt) | 1992-06-18 | 2000-04-28 | Harvard College | Vacinas de toxina da difteria |
| US5856122A (en) | 1993-08-24 | 1999-01-05 | University Of Alberta | Modification of pertussis toxin |
| DE69535002T2 (de) | 1994-03-08 | 2006-12-07 | Memorial Sloan-Kettering Cancer Center | Rekombinante humanisierte antikörper gegen fb5 |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| DE4430721A1 (de) | 1994-08-30 | 1996-03-07 | Hoechst Ag | Autoglanztrocknungsmittel |
| US5843462A (en) | 1995-11-30 | 1998-12-01 | Regents Of The University Of Minnesota | Diphtheria toxin epitopes |
| CA2274806C (en) * | 1996-12-09 | 2011-02-01 | Genencor International, Inc. | H mutant alpha-amylase enzymes |
| WO2001025267A2 (en) | 1999-10-04 | 2001-04-12 | Twinstrand Therapeutics Inc. | Improved ricin-like toxins for treatment of cancer |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US5976806A (en) | 1997-06-25 | 1999-11-02 | Pioneer Hi-Bred International, Inc. | DNA ligase assay |
| US6835550B1 (en) | 1998-04-15 | 2004-12-28 | Genencor International, Inc. | Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| AU4057300A (en) | 1999-03-30 | 2000-10-16 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinacious compounds |
| US6960652B2 (en) | 1999-03-30 | 2005-11-01 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinaceous compounds |
| DE60028248T2 (de) | 1999-12-02 | 2007-03-15 | Thromb-X N.V. | Verfahren zur Reduzierung der Immunogenität von Staphylokinase durch Entfernen von T-Zell-Epitopen |
| US7368532B2 (en) | 1999-12-02 | 2008-05-06 | Syntaxin Limited | Constructs for delivery of therapeutic agents to neuronal cells |
| US20060018885A1 (en) | 2000-11-14 | 2006-01-26 | Ildstad Suzanne T | Methods for increasing HSC graft efficiency |
| US20040256304A1 (en) | 2001-01-19 | 2004-12-23 | Perry Carlos V. | Recirculating filter |
| JP2004519230A (ja) | 2001-02-06 | 2004-07-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 低減された免疫原性を有する修飾されたインターロイキン−１受容体アンタゴニスト（ｉｌ−１ｒａ） |
| CN1491231A (zh) | 2001-02-06 | 2004-04-21 | Ĭ��ר������˾ | 免疫原性减弱的经修饰角质形成细胞生长因子(kgf) |
| KR20030074789A (ko) | 2001-02-06 | 2003-09-19 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 개질된 인간 뇌유래 신경영양인자 (ｂｄｎｆ） |
| CN1491232A (zh) | 2001-02-06 | 2004-04-21 | Ĭ��ר������˾ | 免疫原性减弱的经修饰肥胖蛋白 |
| US20040063917A1 (en) | 2001-02-06 | 2004-04-01 | Carr Francis J. | Modified erythropoietin (epo) with reduced immunogenicity |
| CA2437287A1 (en) | 2001-02-06 | 2002-10-03 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity |
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| US7132511B2 (en) | 2001-02-19 | 2006-11-07 | Merck Patent Gmbh | Modified anti-EGFR antibodies with reduced immunogenicity |
| CN100522242C (zh) | 2001-02-19 | 2009-08-05 | 默克专利有限公司 | 具有降低的免疫原性的人工蛋白质 |
| WO2002069232A2 (en) | 2001-02-19 | 2002-09-06 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
| BR0207542A (pt) | 2001-02-26 | 2004-03-09 | Merck Patent Gmbh | Trombopoietina modificada com imunogenicidade reduzida |
| US20060062761A1 (en) | 2001-03-02 | 2006-03-23 | Carr Francis J | Modified interferon alpha with reduced immunogenicity |
| JP2004529629A (ja) | 2001-03-02 | 2004-09-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 低減された免疫原性を有する修飾された繊毛様神経栄養因子（ｃｎｔｆ） |
| KR20030082962A (ko) | 2001-03-08 | 2003-10-23 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 개질된과립구대식세포집락자극인자(ｇｍ-ｃｓｆ) |
| EP1411969A1 (en) | 2001-03-08 | 2004-04-28 | MERCK PATENT GmbH | Modified protamine with reduced immunogenicity |
| BR0208041A (pt) | 2001-03-15 | 2004-02-25 | Merck Patent Gmbh | Interferon beta modificado com imunogenicidade reduzida |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| WO2002098897A2 (en) | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| WO2003000193A2 (en) | 2001-06-21 | 2003-01-03 | Surromed, Inc. | Covalent coupling of botulinum toxin with polyethylene glycol |
| MXPA03012030A (es) | 2001-06-26 | 2005-07-01 | Agen Biomedical Ltd | Anticuerpos humanizados derivados de dd-3b6/22, especificos para el fragmento de dimero d de fibrina. |
| BR0211091A (pt) | 2001-07-13 | 2004-06-15 | Merck Patent Gmbh | Métodos para redução de imunogenicidade de polipeptìdeos |
| MXPA04001982A (es) | 2001-09-04 | 2004-06-07 | Merck Patent Gmbh | Factor ix modificado. |
| US20050020494A1 (en) | 2001-09-04 | 2005-01-27 | Carr Francis J | Modified human growth hormone |
| ATE469176T1 (de) | 2001-11-12 | 2010-06-15 | Merck Patent Gmbh | Modifizierter anti-tnf antikörper |
| KR20040068561A (ko) | 2001-11-29 | 2004-07-31 | 메르크 파텐트 게엠베하 | 카르복시펩티다아제 ｇ2에서의 ｔ-세포 에피토프 |
| KR20040101428A (ko) | 2002-04-09 | 2004-12-02 | 메르크 파텐트 게엠베하 | 항유전인자형 항-ｃｅａ 항체 분자 및 암백신으로서의이의 용도 |
| WO2003087161A1 (en) | 2002-04-18 | 2003-10-23 | Merck Patent Gmbh | Modified factor viii |
| US20050181459A1 (en) | 2002-06-11 | 2005-08-18 | Matthew Baker | Method for mapping and eliminating T cell epitopes |
| US20040018568A1 (en) | 2002-07-23 | 2004-01-29 | Subhashis Banerjee | Methods for detecting deantigenized T cell epitopes and uses thereof |
| PL372862A1 (en) | 2002-08-09 | 2005-08-08 | Merck Patent Gmbh | T-cell epitopes in erythropoietin |
| US20050240009A1 (en) | 2002-08-21 | 2005-10-27 | Carr Francis J | T-cell epitopes in staphylococcal enterotoxin b |
| CA2509902A1 (en) | 2002-12-13 | 2004-07-01 | Aurelium Biopharma Inc. | Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| EP1581904A2 (en) | 2003-01-08 | 2005-10-05 | Xencor, Inc. | Novel proteins with altered immunogenicity |
| JP2007525458A (ja) | 2003-04-23 | 2007-09-06 | メダレックス インコーポレイテッド | インターフェロンα受容体−１（ＩＦＮＡＲ−１）に対するヒト化抗体 |
| PT1636261E (pt) | 2003-06-26 | 2007-11-08 | Merck Patent Gmbh | Proteínas trombopoietina com propriedades melhoradas |
| WO2004113386A2 (en) | 2003-06-26 | 2004-12-29 | Merck Patent Gmbh | Modified hirudin proteins and t-cell epitopes in hirudin |
| AR045614A1 (es) | 2003-09-10 | 2005-11-02 | Hoffmann La Roche | Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos |
| US20050176028A1 (en) | 2003-10-16 | 2005-08-11 | Robert Hofmeister | Deimmunized binding molecules to CD3 |
| US7264806B2 (en) | 2003-11-01 | 2007-09-04 | Biovation Ltd. | Modified anti-CD52 antibody |
| EP1687016A4 (en) | 2003-11-25 | 2009-07-29 | Anjin Corp | GENETIC VARIANT OF DIPHTHERIC TOXIN |
| US7431720B2 (en) | 2003-11-25 | 2008-10-07 | Ethicon, Inc. | Multi-function clamping device with stapler and ablation heads |
| US20050153872A1 (en) | 2004-01-12 | 2005-07-14 | Xiao-Qing Qiu | Methods and compositions for the treatment of infection |
| US20060228404A1 (en) | 2004-03-04 | 2006-10-12 | Anderson Daniel G | Compositions and methods for treatment of hypertrophic tissues |
| MXPA06010716A (es) | 2004-03-19 | 2007-02-21 | Merck Patent Gmbh | Proteinas bouganin modificadas, citotoxinas y metodos y usos de las mismas. |
| US20060002932A1 (en) | 2004-06-04 | 2006-01-05 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| US20060165687A1 (en) | 2004-10-19 | 2006-07-27 | Duke University | Vaccine adjuvant |
| WO2006044864A2 (en) | 2004-10-19 | 2006-04-27 | Duke University | Vaccine adjuvant |
| CN1314806C (zh) | 2005-01-14 | 2007-05-09 | 四川大学 | 小型化抗eb病毒肿瘤多肽及其应用与制备方法 |
| US20060270600A1 (en) | 2005-05-26 | 2006-11-30 | Eisuke Mekada | Anti-cancer agents |
| US20060269514A1 (en) | 2005-05-27 | 2006-11-30 | Abdul-Rahman Jazieh | Methods and compositions for the modulation of immune responses and cancer diseases |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| US20070250652A1 (en) | 2006-04-24 | 2007-10-25 | Atmel Corporation | High speed dual-wire communications device requiring no passive pullup components |
| US8993295B2 (en) | 2006-07-20 | 2015-03-31 | The General Hospital Corporation | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting |
| WO2008073160A2 (en) | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| AU2008279550B2 (en) | 2007-06-21 | 2012-08-09 | Angelica Therapeutics, Inc. | Modified toxins |
| WO2009110944A1 (en) | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Modified toxins |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| EP2968450A4 (en) | 2013-03-15 | 2016-10-26 | Angelica Therapeutics Inc | MODIFIED TOXINS |
-
2014
- 2014-03-11 EP EP14770668.3A patent/EP2968450A4/en not_active Withdrawn
- 2014-03-11 JP JP2016501335A patent/JP2016519651A/ja active Pending
- 2014-03-11 HK HK16108466.0A patent/HK1220376A1/zh unknown
- 2014-03-11 WO PCT/US2014/023761 patent/WO2014150600A2/en not_active Ceased
- 2014-03-11 US US14/770,763 patent/US10059750B2/en active Active - Reinstated
- 2014-03-11 CA CA2902905A patent/CA2902905A1/en not_active Abandoned